(1 - 14 from 23
)
New FDA lung cancer OK for Celgene's Abraxane should boost sales
www.fiercepharma.com
[FiercePharma] - A much bigger payout, though, could depend on a late-stage study of pancreatic cancer. Success in this indication is seen by some analysts, including TheStreet's Adam Feuerstein, as a potential winner for investors hanging on to the Celgene CVR.
Adam Feuerstein | The Independent
www.independent.co.uk
A Top Puma Bio Exec Resigns Ahead of FDA Panel, Analysts Defend With Conflicting Stories. The surprise exit of Puma's regulatory chief is sparking fears FDA ...
sorted by relevance / date